Article
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Pharmacogenetics and genomics - 1 Apr 2008
Hesselink Dennis A, van Schaik Ron H N, van Agteren Madelon, de Fijter Johannes W, Hartmann Anders, Zeier Martin, Budde Klemens, Kuypers Dirk R J, Pisarski Przemyslav, Le Meur Yann, Mamelok Richard D, van Gelder Teun
Abstract excerpt
OBJECTIVE: Patients expressing the tacrolimus-metabolizing enzyme, cytochrome P450 (CYP) 3A5, require more tacrolimus to reach target concentrations. We studied the influence of the CYP3A5(*)3 allele, which results in the absence of CYP3A5 protein, on tacrolimus dose and exposure, as well as the incidence of biopsy-proven acute rejection (BPAR) after renal transplantation. METHODS: A total of 136 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.